Strategies for Overcoming Drug Interference in Immunogenicity Assessment
Circulating drug can often interfere in the detection of anti-drug antibodies (ADAs). Therefore, it is imperative to develop bioanalytical assays that are able to reliably detect both ADAs as well as neutralizing ADAs (NAbs) in the presence of the drug.
This webinar will provide an overview of the different type of interferences as well as the approaches utilized to optimize drug tolerance.
What will you learn?
- Different types of drug interference
- Immunogenicity assay design and susceptibility to drug interference
- Mitigation strategies
Who may this interest?
- Bioanalytical scientists
- Clinical pharmacologists
- Pharmacokinetic scientists
Speaker
Lynn Kamen, PhD
Scientific Officer, Executive Director
BioAgilytix (CA, USA)
Lynn Kamen earned her PhD in Immunology at the University of Michigan (MI, USA) and completed a postdoctoral fellowship at the University of California San Francisco (CA, USA). She has spent the past decade working in drug development supporting both large and small molecule formats from early target discovery through clinical development. Most recently, she was a principal scientist at Genentech (CA, USA) where she supported large molecule and novel modality bioanalysis including PK, immunogenicity and biomarker.
In association with
